| Provenge (sipuleucel-T) / Bausch Health |
NCT00027599: APC8015 and Bevacizumab in Treating Patients With Prostate Cancer |
|
|
| Completed | 2 | 25 | US | bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T, therapeutic autologous dendritic cells, in vitro-treated peripheral blood stem cell transplantation | National Cancer Institute (NCI) | Prostate Cancer | 07/07 | | | |
NCT00849290: Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442) |
|
|
| Completed | 2 | 113 | Canada, US | APC8015F | Dendreon | Metastatic Androgen Independent Prostate Cancer | 01/09 | 04/09 | | |
ProACT, NCT00715078: To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen |
|
|
| Completed | 2 | 122 | US | sipuleucel-T | Dendreon | Prostate Cancer | 04/12 | 05/15 | | |
| Completed | 2 | 42 | US | Sipuleucel-T with Booster, Sipuleucel-T without Booster | Dendreon, University of California, San Francisco | Prostate Cancer | 12/12 | 12/13 | | |
| Completed | 2 | 47 | Europe | sipuleucel-T, PROVENGE, APC8015 | Dendreon | Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Neoplasms, Prostatic, Prostate Cancer, Prostate Neoplasms, Prostatic Cancer | 06/14 | 06/14 | | |
NCT00901342: Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer |
|
|
| Completed | 2 | 104 | US | sipuleucel-T, • Provenge® • APC8015 | Dendreon | Prostate Cancer | 12/14 | 06/15 | | |
NCT01431391: Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer |
|
|
| Completed | 2 | 68 | US | sipuleucel-T, PROVENGE®, APC8015, leuprolide acetate, Eligard® | Dendreon | Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma | 12/14 | 12/14 | | |
|
|
|
|
NCT01338012: Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer |
|
|
| Terminated | 2 | 8 | US | sipuleucel-T, PROVENGE, APC8015 | Dendreon | Prostate Cancer | 04/15 | 04/15 | | |
NCT02159950: Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer |
|
|
| Completed | 2 | 2 | US | Laboratory Biomarker Analysis, Sipuleucel-T, APC8015, APC8015 Vaccine, PA2024 (PAP/GM-CSF)-Loaded Dendritic Cell Vaccine, Provenge, Tasquinimod, ABR-215050, TASQ | Roswell Park Cancer Institute, Active Biotech AB | Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer | 07/15 | | | |
STAMP, NCT01487863: Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer |
|
|
| Completed | 2 | 69 | US | sipuleucel-T, PROVENGE(R), APC8015, abiraterone acetate, ZYTIGA(R) | Dendreon | Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer | 05/16 | 06/16 | | |
|
|
|
NCT01420965: Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer |
|
|
| Terminated | 2 | 7 | US | CT-011 (Anti-PD1 Antibody), Anti-PD1 Antibody, Sipuleucel-T (Provenge), Provenge, Cyclophosphamide, Cytoxan | Augusta University | Prostatic Neoplasms | 12/16 | 12/16 | | |
NCT01706458: Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer |
|
|
| Completed | 2 | 18 | US | sipuleucel-T, Provenge, DNA Vaccine, pTVG-HP with rhGM-CSF | University of Wisconsin, Madison, Dendreon | Prostate Cancer | 06/17 | 08/20 | | |
STRIDE, NCT01981122: A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer |
|
|
| Completed | 2 | 52 | US | sipuleucel-T, PROVENGE(R), APC8015, enzalutamide, Xtandi | Dendreon | Metastatic Prostate Cancer | 06/17 | 06/17 | | |
|
NCT02793765: Docetaxel Followed by Provenge in Metastatic Prostate Cancer |
|
|
| Withdrawn | 2 | 0 | US | Docetaxel, Taxotere, Docefrez, Sipuleucel-T, Provenge | The University of Texas Health Science Center, Houston | Prostate Cancer | 07/18 | 07/21 | | |
NCT02793219: Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer |
|
|
| Withdrawn | 2 | 0 | US | Sipuleucel-T, Provenge, Docetaxel, Taxotere, Docefrez | The University of Texas Health Science Center, Houston | Prostate Cancer | 07/18 | 07/21 | | |
NCT01560923: Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer |
|
|
| Completed | 2 | 47 | US | Indoximod, 1-methyl-D-tryptophan, Sipuleucel-T, Provenge, Placebo | Masonic Cancer Center, University of Minnesota | Metastatic Prostate Cancer | 12/18 | 12/18 | | |
|
NCT01807065: Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer |
|
|
| Completed | 2 | 51 | US | sipuleucel-T, APC 8015, Provenge, external beam radiation therapy, EBRT, laboratory biomarker analysis | City of Hope Medical Center, National Cancer Institute (NCI) | Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Soft Tissue Metastases, Stage IV Prostate Cancer | 12/18 | 12/19 | | |
NCT02463799: Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC |
|
|
| Completed | 2 | 36 | US | Radium-223, Xofigo, BAY88-8223, Sipuleucel-T, Provenge | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dendreon, Bayer | Prostate Cancer | 12/19 | 12/19 | | |
NCT01818986: Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) |
|
|
| Completed | 2 | 20 | US | Sipuleucel-T, Provenge, Stereotactic Ablative Body Radiation, SABR | University of Texas Southwestern Medical Center | Metastatic Castrate-resistant Prostate Cancer, mCRPC | 12/19 | 05/21 | | |
NCI-2014-00318, NCT01804465: Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer |
|
|
| Completed | 2 | 50 | US | SipT Treatment, Provenge, Ipilimumab, BMS-734016/MDX-010, anti-CTLA4 | University of California, San Francisco, M.D. Anderson Cancer Center, Bristol-Myers Squibb, Dendreon | Prostate Cancer | 02/20 | 08/20 | | |
NCT05751941: Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer |
|
|
| Recruiting | 2 | 26 | US | Abiraterone, Enzalutamide, Xtandi, Apalutamide, Sipuleucel-T, Provenge | H. Lee Moffitt Cancer Center and Research Institute, Dendreon | Prostate Cancer, Metastatic Prostate Cancer | 10/25 | 10/25 | | |
NCT06100705: Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC |
|
|
| Recruiting | 2 | 26 | US | Testosterone Cypionate, DEPO-Testosterone, Sipuleucel-T, Provenge | Yale University, Dendreon | Metastatic Castration-resistant Prostate Cancer | 12/27 | 03/28 | | |
